Vaxart, Inc. reported financial results for the second quarter ended June 30, 2026, and provided a business update on its oral vaccine programs. The company reported a net loss of $13.5 million ($0.06 per share) on revenue of $27.2 million, which was primarily driven by its BARDA government contract. As of June 30, 202...

Verastem Oncology reported financial results for the second quarter ended June 30, 2026, highlighted by $25.1 million in net product revenue from AVMAPKI FAKZYNJA CO-PACK, its first commercial product approved in May 2025. Total revenue reached $40.1 million, including a $15 million milestone payment from Secura Bio. T...

Verrica Pharmaceuticals reported second quarter 2026 financial results, highlighted by record demand for YCANTH. Total revenue for the quarter was $5.9 million, down from $12.7 million in Q2 2025, primarily due to a one-time $8.0 million milestone payment in the prior year. However, U.S. YCANTH net product revenue grew...

Viridian Therapeutics reported second quarter 2026 financial results and provided significant business updates. The company achieved a major milestone with the FDA approval of Lumvoa™ (veligrotug-vvze) for thyroid eye disease (TED) on June 26, 2026, marking its transition to a commercial-stage company. Early launch ind...

Vistagen Therapeutics announced topline results from an exploratory Phase 2 study evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder (SAD). The three-arm, randomized, double-blind trial (N=61) assessed a repeat dose regimen (two 3.2 µg doses ten minutes apart) against a single dose and...